“With ENVASARC fully enrolled we are focused on leveraging our Product Development Platform to generate non-dilutive capital through either an additional license or by replacing a CRO and executing clinical trials for partners at a lower cost compared to a CRO but still at a premium to our costs using a pay for performance model,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. “We look forward to reporting the final response assessment data in all patients from the ENVASARC Phase 2 pivotal trial, which are expected in the third quarter.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCON:
- TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- David Lazar Joins TRACON Pharmaceuticals as Chief Business Officer
- TCON Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
- Tracon Pharmaceuticals files to sell common stock, warrants, no amount given
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue